Cargando…
Complement inhibition in severe COVID-19 – Blocking C5a seems to be key
Autores principales: | Lim, Endry H.T., Vlaar, Alexander P.J., de-Bruin, Sanne, Brouwer, Matthijs C., van-de-Beek, Diederik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099654/ https://www.ncbi.nlm.nih.gov/pubmed/33997737 http://dx.doi.org/10.1016/j.eclinm.2021.100722 |
Ejemplares similares
-
Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
por: Vlaar, Alexander P J, et al.
Publicado: (2021) -
Inhibiting C5 in patients with severe COVID-19—the incorrect target?
por: Lim, Endry H T, et al.
Publicado: (2023) -
Complement activation in COVID-19 and targeted therapeutic options: A scoping review
por: Lim, Endry Hartono Taslim, et al.
Publicado: (2023) -
Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author's reply
por: Annane, Djillali, et al.
Publicado: (2021) -
The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19
por: Vlaar, Alexander P. J., et al.
Publicado: (2022)